NO20005637L - Hybrid protein to inhibit mastocyte degranulation and its use - Google Patents

Hybrid protein to inhibit mastocyte degranulation and its use

Info

Publication number
NO20005637L
NO20005637L NO20005637A NO20005637A NO20005637L NO 20005637 L NO20005637 L NO 20005637L NO 20005637 A NO20005637 A NO 20005637A NO 20005637 A NO20005637 A NO 20005637A NO 20005637 L NO20005637 L NO 20005637L
Authority
NO
Norway
Prior art keywords
inhibit
hybrid protein
mastocyte degranulation
mastocyte
degranulation
Prior art date
Application number
NO20005637A
Other languages
Norwegian (no)
Other versions
NO328361B1 (en
NO20005637D0 (en
Inventor
Hans Bigalke
Juergen Frevert
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Publication of NO20005637L publication Critical patent/NO20005637L/en
Publication of NO20005637D0 publication Critical patent/NO20005637D0/en
Publication of NO328361B1 publication Critical patent/NO328361B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)

Abstract

The invention relates to a hybrid protein comprising or comprised of (i) a known protein which binds to mastocytes and/or basophils in a known manner and/or is absorbed thereby, and of (ii) a protease which splits one or more proteins of the secretory apparatus of the mastocytes and/or basophils.
NO20005637A 1998-05-13 2000-11-08 Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation NO328361B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (en) 1998-05-13 1999-05-12 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Publications (3)

Publication Number Publication Date
NO20005637L true NO20005637L (en) 2000-11-08
NO20005637D0 NO20005637D0 (en) 2000-11-08
NO328361B1 NO328361B1 (en) 2010-02-01

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005637A NO328361B1 (en) 1998-05-13 2000-11-08 Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation

Country Status (21)

Country Link
EP (1) EP1084146B1 (en)
JP (1) JP4549533B2 (en)
KR (1) KR100580541B1 (en)
CN (1) CN1241945C (en)
AT (1) ATE227739T1 (en)
AU (1) AU755513B2 (en)
BR (1) BR9910359A (en)
CA (1) CA2331274C (en)
CU (1) CU22997A3 (en)
CZ (1) CZ294376B6 (en)
DE (1) DE59903410D1 (en)
DK (1) DK1084146T3 (en)
ES (1) ES2187200T3 (en)
HU (1) HUP0103601A3 (en)
IL (2) IL139478A0 (en)
MX (1) MXPA00011148A (en)
NO (1) NO328361B1 (en)
PL (1) PL201879B1 (en)
PT (1) PT1084146E (en)
RU (1) RU2214420C2 (en)
WO (1) WO1999058571A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
RU2255761C1 (en) * 2004-07-01 2005-07-10 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Preparation for treatment of muscular dystonia from toxin of culture clostridium botulinum and method for its preparing
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (en) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 Peptides Inducing Activity of Mast Cells and Immune Modulators Comprising the Same
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
CA2726092A1 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
BRPI0916615A2 (en) * 2008-07-31 2015-08-04 Total Sa Constructs and methods for polypeptide production and secretion
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (en) * 2010-05-27 2014-05-14 四川大学 Recombinant IgE-Fc-anti EGFR single chain variable fragment fusion protein, its preparation method and its application
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PT3242884T (en) 2015-01-09 2021-04-22 Ipsen Bioinnovation Ltd Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
US20250066755A1 (en) 2021-03-30 2025-02-27 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
AU2022247196A1 (en) 2021-03-30 2023-10-05 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (en) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Use of 2-methoxyestradiol in the treatment of mastocytosis
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1237972A1 (en) * 1983-01-07 1986-06-15 Киевский научно-исследовательский институт отоларингологии им.проф.А.И.Коломийченко Method of determining activity of inhibitor of mastocytes degranulation
US4902495A (en) * 1986-07-22 1990-02-20 The United States Of America As Represented By The Department Of Health And Human Services IgE Fc directed delivery system
RU2030914C1 (en) * 1992-09-15 1995-03-20 Людмила Михайловна Огородова Agent preventing degranulation of mast cells
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
CN1300295A (en) 2001-06-20
HUP0103601A3 (en) 2004-06-28
AU4260599A (en) 1999-11-29
RU2214420C2 (en) 2003-10-20
HK1036994A1 (en) 2002-01-25
EP1084146A2 (en) 2001-03-21
CA2331274C (en) 2010-04-06
JP2002514659A (en) 2002-05-21
JP4549533B2 (en) 2010-09-22
CU22997A3 (en) 2004-10-12
BR9910359A (en) 2001-01-09
KR20010042825A (en) 2001-05-25
HUP0103601A2 (en) 2002-01-28
PT1084146E (en) 2003-02-28
CZ20004161A3 (en) 2001-04-11
DE59903410D1 (en) 2002-12-19
PL201879B1 (en) 2009-05-29
CZ294376B6 (en) 2004-12-15
EP1084146B1 (en) 2002-11-13
MXPA00011148A (en) 2003-04-22
AU755513B2 (en) 2002-12-12
NO328361B1 (en) 2010-02-01
CA2331274A1 (en) 1999-11-18
IL139478A (en) 2008-06-05
DK1084146T3 (en) 2003-02-03
WO1999058571A3 (en) 2000-02-03
CN1241945C (en) 2006-02-15
KR100580541B1 (en) 2006-05-16
ATE227739T1 (en) 2002-11-15
WO1999058571A2 (en) 1999-11-18
ES2187200T3 (en) 2003-05-16
IL139478A0 (en) 2001-11-25
NO20005637D0 (en) 2000-11-08
PL344752A1 (en) 2001-11-19

Similar Documents

Publication Publication Date Title
NO20005637L (en) Hybrid protein to inhibit mastocyte degranulation and its use
BR9407377A (en) Hybrid toxin
ATE317441T1 (en) CATHEPSIN-02 PROTEASE
EP1905830B8 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
ATE304592T1 (en) AUTOMATION IN PROTEIN DESIGN THROUGH PROTEIN LIBRARIES
ATE321066T1 (en) ANTI-HER2 ANTIBODY COMPOSITION
MXPA03010762A (en) Iap binding peptides and assays for identifying compounds that bind iap.
DE60019458D1 (en) STABILIZING DILUENT FOR POLYPEPTIDES AND ANTIGENES
UY28641A1 (en) ANTIBODIES
EP1970070A3 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE50307984D1 (en) Streptavidin binding peptide
FR2816410B1 (en) ESM-1 PROTEIN DETECTION KIT AND DETECTION METHOD USING THE SAME
IL145689A0 (en) Methods
CY1110381T1 (en) X-CONOTOXIN Peptides as Neuronal Amine Transport Inhibitors
PT723552E (en) OLIGOPEPTIDES DERIVED FROM REAGENT PROTEIN FRAGMENTS
NO20055210D0 (en) Inhibitor proteins of a protease and its use
DE69133166D1 (en) INHIBITORS OF CATALYTIC ANTIBODIES
ATE309363T1 (en) HYBRID TOXINS OF BACILLUS THURINGIENSIS
CY1109904T1 (en) IL-18BP PRODUCER, ITS PREPARATION AND USE
ATE433953T1 (en) PEPTIDE DEFORMYLAS INHIBITORS
AU2003280359A1 (en) Phosphoamidase assay
TNSN99075A1 (en) SYNTHETIC SIGNAL SEQUENCE FOR PROTEIN SECRETION IN STREPTOMYCES AND ACTINOMYCETS.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees